Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 5/20 | 0.48 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409991 | 0.88 | PKM (0.56) | KMT2AMEN1ALDH1A1GAAPOLB | |
| SCHEMBL6407018 | 0.74 | TACR1 (0.56) | KMT2AMEN1TACR1MAPT | |
| SCHEMBL6409563 | 0.74 | ALDH1A1 (0.50) | KMT2AMEN1ALDH1A1LMNAGAA | |
| SCHEMBL6410627 | 0.74 | TACR1 (0.53) | TACR1 | |
| SCHEMBL4487177 | 0.72 | TACR1 (0.55) | KMT2AALDH1A1TACR1 | |
| SCHEMBL6408396 | 0.71 | TACR1 (0.53) | TACR1 | |
| SCHEMBL6410854 | 0.70 | TACR1 (0.55) | TACR1 | |
| SCHEMBL6408869 | 0.70 | TACR1 (0.85) | TACR1 | |
| SCHEMBL4481859 | 0.69 | TACR1 (0.48) | ALDH1A1KDM4ETACR1MAPTL3MBTL1 | |
| SCHEMBL6411909 | 0.68 | TACR1 (0.67) | KMT2AMEN1TACR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-02-17 | — | — | US | disclosed |
| EP-1460062-A1 | NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | BDKRB1, BDKRB2, TACR1 | KMT2A 2257/4885MEN1 2432/4885ALDH1A1 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.